| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Thyrotropin-releasing hormone receptor, TRH-R, Thyroliberin receptor, TRHR |
| Entrez GeneID | 7201 |
| WB Predicted band size | 45.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This TRHR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 209-238 amino acids from the Central region of human TRHR. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于TRHR抗体的3篇参考文献示例(内容为虚构，仅作格式参考)：
1. **文献名称**：*Autoantibodies against TRHR in Graves' Disease: Clinical Implications*
**作者**：Smith A, et al.
**摘要**：该研究检测了Graves'病患者血清中的TRHR自身抗体水平，发现其与甲状腺功能亢进症状严重程度相关，提示TRHR抗体可能参与自身免疫性甲状腺疾病的病理机制。
2. **文献名称**：*Development of a Monoclonal TRHR Antibody for Targeting Neuroendocrine Tumors*
**作者**：Johnson R, et al.
**摘要**：研究团队开发了一种靶向TRHR的单克隆抗体，并在神经内分泌肿瘤模型中验证其结合能力，表明其在肿瘤诊断或靶向治疗中的潜在应用价值。
3. **文献名称**：*TRHR Antibody Modulates Receptor Signaling in Hypothalamic Neurons*
**作者**：Lee S, et al.
**摘要**：通过体外实验证明，TRHR抗体可竞争性抑制促甲状腺激素释放激素(TRH)与受体的结合，影响下游信号通路，为研究TRHR在神经内分泌调控中的作用提供了新工具。
(注：以上文献及内容为示例性质，实际文献需通过学术数据库检索获取。)
TRHR antibodies target the thyrotropin-releasing hormone receptor (TRHR), a G protein-coupled receptor (GPCR) primarily expressed in the anterior pituitary gland. TRHR binds thyrotropin-releasing hormone (TRH), a hypothalamic peptide, to regulate the secretion of thyroid-stimulating hormone (TSH) and prolactin. Beyond the pituitary, TRHR is found in peripheral tissues, including the brain, pancreas, and certain cancers, suggesting broader physiological and pathological roles.
Research on TRHR antibodies has focused on their utility in studying receptor localization, signaling pathways, and disease mechanisms. In autoimmune thyroid disorders, autoantibodies against TRHR have been explored but remain less characterized compared to TSH receptor antibodies. Synthetic or monoclonal TRHR antibodies are also used experimentally to modulate receptor activity, either as agonists or antagonists, offering insights into TRHR's role in metabolic regulation, mood disorders, and cancer progression.
Recent studies highlight TRHR's overexpression in cancers like prostate and breast tumors, making it a potential therapeutic target. Antibodies targeting TRHR could enable drug delivery or receptor inhibition in malignancies. However, challenges persist in developing clinically viable TRHR antibodies due to receptor structural complexity and cross-reactivity risks. Current work emphasizes improving antibody specificity and evaluating their diagnostic/therapeutic potential in endocrine and oncological contexts.
×
